Skip to content
Translational Neuropharmacology Lab (Zanos Lab)

Translational Neuropharmacology Lab (Zanos Lab)

Our laboratory, based in Cyprus, employs molecular and systems neuroscience, behavioral pharmacology, as well as advanced computational methods to unravel the mysteries of brain diseases and identify targets for the development of novel and effective pharmacotherapies.

Menu
  • Home
  • News
  • Team Members
    • Lab Director
    • Current Team Members
    • Alumni
  • Research
  • Research Units
    • Translational Neuropharmacology Unit
    • Clinical Neuropsychopharmacology Unit
    • AI & Systems Bioinformatics Unit Cyprus
    • Genetic Epidemiology Unit
  • Facilities
  • Publications
  • Media
  • Join Us
  • Contact
  • More

Dr. Anna Onisiforou

Dr. Anna Onisiforou, BA, BSc, MSc, MSc, Ph.D.

Senior Scientist

Head of the AI & Systems Bioinformatics Unit

Dr. Onisiforou holds a B.Sc. (Hons) in Natural Sciences with direction in Biology and Chemistry, a M.Sc. in Medicinal Chemistry, and a Ph.D. in Neuroscience. She also holds a B.A. (Hons) in Accounting and Finance and a M.Sc. in Finance and Financial Law.

Her current research work is centered on the investigation of microbial pathogenesis in neurodegenerative diseases. Meanwhile, her ongoing project involves a human clinical trial, where she examines ketamine-induced changes in EEG activity, gene expression, and treatment response in patients dealing with comorbid opioid addiction and depression.

Research Interests: Her research interests include neurodegenerative and autoimmune diseases, with a particular focus on the role of microbial organisms in their development. She specializes in the development and application of computational methods, such as multi-omics analysis and network-based approaches. Currently, she is integrating her computational expertise with experimental methods in the fields of addictions and neuropsychiatric disorders.

Selected Publications:

  • Georgiou, A., Zanos, P., Onisiforou, A. Metformin Shows Greater Potential Than Semaglutide in Reducing Alzheimer’s Risk in Diabetes Type II via Dual Actions: Tackling Disease Pathways and Environmental Herpesvirus Triggers. bioRxiv. 2025. https://doi.org/10.1101/2025.03.14.643306.
  • Onisiforou, A., Koumas, M., Michael, A., Zanos, P. Selective transcriptomic recovery by (2R,6R)-hydroxynorketamine in opioid-abstinent mice: Machine learning identifies predictive biomarkers. bioRxiv. 2025. https://doi.org/10.1101/2025.06.04.657935.
  • Michael, A.*, Onisiforou, A.*, Georgiou, P., Koumas, M., Powels, C., Mammadov, E., Georgiou A.N., Zanos, P. (2R,6R)-hydroxynorketamine prevents opioid abstinence-related negative affect and stress-induced reinstatement in mice. British Journal of Pharmacology, 2025, In Press. * Equal contribution. https://doi.org/10.1111/bph.70018.
  • Onisiforou, A., Charalambous, E., Zanos, P. Shattering the Amyloid Illusion: The Microbial Enigma of Alzheimer’s Disease Pathogenesis—From Gut Microbiota and Viruses to Brain Biofilms. Microorganisms. 2025, 13(1), 90. https://doi.org/10.3390/microorganisms13010090
  • Onisiforou, A., Zanos, P. One path, two solutions: Network-based analysis identifies targetable pathways for the treatment of comorbid type II diabetes and neuropsychiatric disorders, Computational & Structural Biotechnology Journal, 2024, 23, 3610-3624. https://doi.org/10.1016/j.csbj.2024.10.011
  • Onisiforou, A., Zanos, P. From viral infections to Alzheimer’s Disease: Unveiling the mechanistic links through Systems Bioinformatics. Journal of Infectious Diseases, 2024, 230, S128–S140. https://doi.org/10.1093/infdis/jiae242.
  • Onisiforou, A., Christodoulou, P., Zamba-Papanicolaou, E., Zanos P., Georgiou P. Transcriptomic Analysis Reveals Sex-Specific Patterns in the Hippocampus in Alzheimer’s Disease. Frontiers in Endocrinology, 2024, 15. https://doi.org/10.3389/fendo.2024.1345498.
  • Michael, A.*, Onisiforou, A.*, Georgiou, P., Koumas, M., Mammadov, E., Zanos, P. (2R,6R)-hydroxynorketamine facilitates extinction and prevents emotional impairment and stress-induced reinstatement in morphine abstinent mice. bioRxiv (2023), 12.07.570550. * Equal Contribution. https://doi.org/10.1101/2023.12.07.570550.
  • Onisiforou A., Zanos P. From Viral Infections to Alzheimer’s Disease: Unveiling the Mechanistic Links Through Systems Bioinformatics. bioRxiv (2023), 12.05.570187. https://doi.org/10.1101/2023.12.05.570187.
  • Christodoulou C*, Onisiforou A*, Zanos P, Zamba-Papanicolaou E. Unraveling the transcriptomic signatures of Parkinson’s Disease and Major Depression using single-cell and bulk data. Frontiers Aging Neuroscience (2023) 15:  doi: 10.3389/fnagi.2023.1273855. *Equal Contribution. https://doi.org/10.3389/fnagi.2023.1273855.
  • Onisiforou A, Spyrou GM. Systems Bioinformatics Reveals Possible Relationship between COVID-19 and the Development of Neurological Diseases and Neuropsychiatric Disorders. Viruses (2022) 14:2270. https://doi.org/10.3390/v14102270.
  • Onisiforou A, Spyrou GM. Immunomodulatory effects of microbiota-derived metabolites at the crossroad of neurodegenerative diseases and viral infection: network-based bioinformatics insights. Frontiers in Immunology (2022) 13. https://doi.org/10.3389/fimmu.2022.843128.
  • Onisiforou A, Spyrou GM. Identification of viral-mediated pathogenic mechanisms in neurodegenerative diseases using network-based approaches. Briefings in Bioinformatics (2021) 22. https://doi.org/10.1093/bib/bbab141.

Contact info:

E-mail: onisiforou.anna@ucy.ac.cy

ORCID: https://orcid.org/0000-0003-3380-7356

 

 

Recent Posts

  • New pre-print: VirTarget framework reveals how Multiple Sclerosis immunotherapies engage with Epstein-Barr Virus-driven disease mechanisms November 6, 2025
  • New preprint: VirTrack framework reveals stage-specific EBV pathogenesis in Multiple Sclerosis October 26, 2025
  • Translational Neuropharmacology Lab presents on novel therapies for brain disorders October 25, 2025
  • Dr. Zanos was invited and presented on antidepressant mechanisms of action of ketamine and other rapid-acting antidepressants at the 6th German-Cypriot Psychotherapy Conference October 7, 2025
  • Featured in Nature Mental Health: Advancing ketamine research and brain pathology treatments October 3, 2025

Navigation

  • Home
  • News
  • Team Members
    • Lab Director
    • Current Team Members
    • Alumni
  • Research
  • Research Units
    • Translational Neuropharmacology Unit
    • Clinical Neuropsychopharmacology Unit
    • AI & Systems Bioinformatics Unit Cyprus
    • Genetic Epidemiology Unit
  • Facilities
  • Publications
  • Media
  • Join Us
  • Contact
  • More

Translational Neuropharmacology Lab (Zanos Lab) 2025 . Powered by WordPress